Clinical Trial Update: Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Gallium-68 PSMA-11 PET/CT and Fluorine-18 Fluciclovine PET/CT imaging in men with recurrent prostate cancer after surgery has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Recurrent Prostate Carcinoma | Phase 2 | Status: COMPLETED